296 related articles for article (PubMed ID: 12431818)
21. Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy.
Beecken WD; Engl T; Jonas D; Blaheta RA
Int J Mol Med; 2009 Feb; 23(2):261-6. PubMed ID: 19148551
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis inhibitors in the treatment of prostate cancer.
Kluetz PG; Figg WD; Dahut WL
Expert Opin Pharmacother; 2010 Feb; 11(2):233-47. PubMed ID: 20088745
[TBL] [Abstract][Full Text] [Related]
23. Role of angiogenesis in tumor growth and metastasis.
Folkman J
Semin Oncol; 2002 Dec; 29(6 Suppl 16):15-8. PubMed ID: 12516034
[TBL] [Abstract][Full Text] [Related]
24. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of angiogenesis in cancers.
Pang RW; Poon RT
Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
[TBL] [Abstract][Full Text] [Related]
26. The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB; Dahut WL
Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
[TBL] [Abstract][Full Text] [Related]
27. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapeutic approaches for hormone-refractory prostate cancer.
Stavridi F; Karapanagiotou EM; Syrigos KN
Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
[TBL] [Abstract][Full Text] [Related]
29. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
[TBL] [Abstract][Full Text] [Related]
30. [Angiogenesis--anti-angiogenesis. Significance for tumor growth and metastasis].
Kunz M; Hartmann A
Hautarzt; 2002 Jun; 53(6):373-84. PubMed ID: 12132293
[TBL] [Abstract][Full Text] [Related]
31. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy.
Li B; Zhang LJ; Zhang ZL; Long M; Ren JH; Lin F; Wang X; Wei JX; Dong K; Zhang HZ
Anticancer Drugs; 2011 Mar; 22(3):213-22. PubMed ID: 21150773
[TBL] [Abstract][Full Text] [Related]
32. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
[TBL] [Abstract][Full Text] [Related]
33. [Recent studies on anti-angiogenesis in cancer therapy].
Kishi K; Milas L; Hunter N; Sato M
Nihon Rinsho; 2000 Aug; 58(8):1747-62. PubMed ID: 10944947
[TBL] [Abstract][Full Text] [Related]
34. The rationale and future potential of angiogenesis inhibitors in neoplasia.
Gasparini G
Drugs; 1999 Jul; 58(1):17-38. PubMed ID: 10439927
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis inhibition in the treatment of prostate cancer.
Madan RA; Dahut WL
Anticancer Agents Med Chem; 2009 Dec; 9(10):1070-8. PubMed ID: 19719453
[TBL] [Abstract][Full Text] [Related]
36. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
38. Targeting Angiogenesis in Prostate Cancer.
Melegh Z; Oltean S
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151317
[TBL] [Abstract][Full Text] [Related]
39. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.
Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA
Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
